GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Total Assets

HLVX (HilleVax) Total Assets : $192.69 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is HilleVax Total Assets?

HilleVax's Total Assets for the quarter that ended in Dec. 2024 was $192.69 Mil.

During the past 12 months, HilleVax's average Total Assets Growth Rate was -48.10% per year. During the past 3 years, the average Total Assets Growth Rate was 101.60% per year.

During the past 5 years, HilleVax's highest 3-Year average Total Assets Growth Rate was 848.40%. The lowest was 101.60%. And the median was 475.00%.

Total Assets is connected with ROA %. HilleVax's annualized ROA % for the quarter that ended in Dec. 2024 was -65.71%. Total Assets is also linked to Revenue through Asset Turnover. HilleVax's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.


HilleVax Total Assets Historical Data

The historical data trend for HilleVax's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Total Assets Chart

HilleVax Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
0.51 127.16 317.21 344.43 192.69

HilleVax Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 344.43 314.18 276.93 220.62 192.69

HilleVax Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

HilleVax's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=154.486+38.204
=192.69

HilleVax's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=154.486+38.204
=192.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HilleVax  (NAS:HLVX) Total Assets Explanation

Total Assets is connected with ROA %.

HilleVax's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-135.788/( (220.622+192.69)/ 2 )
=-135.788/206.656
=-65.71 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

HilleVax's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (220.622+192.69)/ 2 )
=0/206.656
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

HilleVax Total Assets Related Terms

Thank you for viewing the detailed overview of HilleVax's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax Business Description

Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, Boston, MA, USA, 02118
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Executives
Robert Hershberg director, officer: President and CEO 3005 FIRST AVENUE, SEATTLE WA 98121
Shane Maltbie officer: Chief Financial Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Aditya Kohli director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Astrid Borkowski officer: Chief Medical Officer C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda director C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu director ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David A Socks officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130